Drug
Ulixertinib clinical trials
Also written BVD-523 and VRT752271.
- studies test it
- 16
- open now
- 4
- in phase 3
- 0
- first study started
- 2013
Keep track of what changes. Save the ulixertinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
16 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 7
- Phase 2
- 11
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 11
BioMed Valley Discoveries, Inc (5) · National Cancer Institute (NCI) (4) · Memorial Sloan Kettering Cancer Center (2) · University of Utah (1) · UNC Lineberger Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · Dana-Farber Cancer Institute (1) · Washington University School of Medicine (1)
Often tested with
Tested in the same studies.
Palbociclib (3) · Erdafitinib (2) · Larotrectinib (2) · Hydroxychloroquine (2) · Adavosertib (1) · Afatinib (1) · Binimetinib (1) · Capivasertib (1)
Studies
Open first, then newest update. How each study uses ulixertinib is read from its arms, and is right about nine times in ten.
Testing it · 16
- Ulixertinib in People With Histiocytic NeoplasmsRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06411821Written as Ulixertinib
- Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid TumorsRecruitingPhase 1UNC Lineberger Comprehensive Cancer CenterNCT03454035Written as Ulixertinib
- A Study of Ruxolitinib in Combination With Ulixertinib in People With MyelofibrosisRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT06773195Written as Ulixertinib
- Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated GliomasRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT05804227Written as Ulixertinib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Ulixertinib
- Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06400225Written as Ulixertinib
- Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT03698994Written as Ulixertinib
- A Phase II Study of BVD-523 in Metastatic Uveal MelanomaTerminatedPhase 2Dana-Farber Cancer InstituteNCT03417739Written as BVD-523
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT03155620Written as Ulixertinib
- Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) MalignanciesTerminatedPhase 2BioMed Valley Discoveries, IncNCT05221320Written as Ulixertinib
- Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal AdenocarcinomasCompletedPhase 1University of UtahNCT04145297Written as Ulixertinib
- Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF AlterationsTerminatedPhase 2BioMed Valley Discoveries, IncNCT04488003Written as Ulixertinib
- BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic CancerTerminatedPhase 1Washington University School of MedicineNCT02608229Written as BVD-523
- Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced MalignanciesCompletedPhase 1/2BioMed Valley Discoveries, IncNCT01781429Written as BVD-523
- Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in VolunteersCompletedPhase 1BioMed Valley Discoveries, IncNCT02994732Written as [14C]-BVD-523
- Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromesCompletedPhase 1/2BioMed Valley Discoveries, IncNCT02296242Written as BVD-523
Given in every arm · 1 — ulixertinib is usual care beside what is tested
Codes
What other systems call ulixertinib · ClinicalTrials.gg INT000666
- MeSH (NLM) C000618314ulixertinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 16ZDH50O1UULIXERTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27089081ulixertinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C104744UlixertinibOne source FDA
- DrugBank DB13930One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000618314 | ulixertinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 16ZDH50O1U | ULIXERTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27089081 | ulixertinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C104744 | Ulixertinib | One source FDA |
| DrugBank | DB13930 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.